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Background: The European Academy of Allergy and Clinical Immunology is in the process of developing its
Guideline for Food Allergy and Anaphylaxis, and this systematic review is one of seven inter-linked evidence
syntheses that are being undertaken in order to provide a state-of-the-art synopsis of the current evidence base in
relation to epidemiology, prevention, diagnosis and clinical management and impact on quality of life, which will
be used to inform clinical recommendations.
The aims of this systematic review will be to assess the effectiveness of interventions for the acute management of
anaphylaxis, and pharmacological and non-pharmacological approaches for the long-term management of
anaphylaxis.
Methods: A highly sensitive search strategy has been developed, and validated study design filters will be applied
to retrieve all articles pertaining to the management of anaphylaxis from electronic bibliographic databases. We will
systematically review the literature on the acute management of anaphylaxis by assessing the effectiveness of
epinephrine, H1-antihistamines (versus placebo), systemic glucocorticosteroids, methylxanthines or any other
treatments for the emergency management of people experiencing anaphylaxis. The main interventions that have
been studied in the context of long-term management are anaphylaxis management plans and allergen-specific
immunotherapy.
Discussion: There is at present little in the way of robust evidence to guide decisions on the acute and/or long-term
management of anaphylaxis. Given the risk of death and the considerable morbidity associated with anaphylaxis these
evidence gaps need to be filled wherever possible; this systematic review will make a start in this area.
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Anaphylaxis can be defined as a “severe, life-threatening
generalised or systemic hypersensitivity reaction” [1,2].
Several working definitions of anaphylaxis have been for-
mulated to aid clinical diagnosis and management [3-6].
The most well-known of these is the consensus clinical
definition proposed by Sampson et al., which involved
representatives of a number of international allergy orga-
nisations, including the European Academy of Allergy
and Clinical Immunology (EAACI) [7].
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reproduction in any medium, provided the orconsiderations, which aim to reduce the risk of further
reactions and improve outcomes if, despite these measures,
a further reaction ensues [8]. Although a self-limiting con-
dition in the majority of cases, it is at present difficult to
predict the severity of future reactions. Fatalities often
occur within minutes of the onset of a reaction; underscor-
ing the importance of effective, emergency management of
reactions [9,10]. The prompt administration of epinephrine
(adrenaline) is particularly important, but although poten-
tially life-saving, evidence indicates that this is under-used
both by patients/carers and professionals [11]. A range of
second-line treatments are also sometimes recommended
[12]. There are furthermore a number of pharmacological
and non-pharmacological approaches that can be used to
try and minimise future risk, but the effectiveness andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clear [13].
The EAACI is in the process of developing the EAACI
Guideline for Food Allergy and Anaphylaxis, and this
systematic review is one of seven inter-linked evidence
syntheses that are being undertaken in order to provide
a state-of-the-art synopsis of the current evidence base
in relation to epidemiology, prevention, diagnosis and
clinical management and impact on quality of life, which
will be used to inform clinical recommendations.
Aims
The aims of this systematic review will be to assess the
effectiveness of interventions for the:
 Acute management of anaphylaxis
 Pharmacological and non-pharmacological
approaches for the long-term management of
anaphylaxis.
Methods
Search strategy
A highly sensitive search strategy has been developed, and
validated study design filters will be applied to retrieve all
articles pertaining to the management of anaphylaxis from
electronic bibliographic databases. We have conceptualised
the search to incorporate three elements, as shown in
Figure 1.
To retrieve systematic reviews, we will use the system-
atic review filter developed at McMaster University
Health Information Research Unit (HIRU) [14]. To re-
trieve randomised controlled trials (RCTs), we will apply
the Cochrane highly sensitive search strategy for identi-
fying randomised trials in MEDLINE: sensitivity- and
precision-maximising version (2008 revision); Ovid for-
mat from Chapter 6 of the Cochrane Handbook [15].
To retrieve non-randomised studies, i.e. controlled cli-
nical trials (CCT), controlled before-and-after (CBA)
and interrupted time-series (ITS) studies, we will use
the Cochrane Effective Practice and Organisation ofCondition
• Anaphylaxis
Interventions
• Acute managment
• Long-term 
management 
considerations
Figure 1 Conceptualisation of systematic review of interventions forCare (EPOC) filter Version 2.4, available on request
from the EPOC Group [16,17]. To retrieve case series,
we used the filter developed by librarians at Clinical
Evidence [18].
We will search the following databases:
 Cochrane Library including,
◦ Cochrane Database of Systematic Reviews (CDSR)
◦ Database of Reviews of Effectiveness (DARE)
◦ CENTRAL (Trials)
◦ Methods Studies
◦ Health Technology Assessments (HTA)
◦ Economic Evaluations Database (EED)
 MEDLINE (OVID)
 Embase (OVID)
 CINAHL (Ebscohost)
 ISI Web of Science (Thomson Web of Knowledge)
 TRIP Database (www.tripdatabase.com)
 Clinicaltrials.gov (National Institutes of Health web).
The search strategy has been developed on OVID
MEDLINE and then adapted for the other databases (see
Additional file 1 for full search strategies). In all cases
the databases will be searched from inception to 30
September 2012. All references will be imported into
an EndNote Library and tagged with the name of the
database. Additional references will be located through
searching the references cited by the identified studies,
and unpublished work and research in progress will be
identified through discussion with experts in the field.
We will invite experts who are active in the field from a
range of disciplines and geography to comment on our
search strategy, and the list of included studies. There
are no language restrictions and, where possible, all lit-
erature will be translated.
Inclusion criteria
 Systematic reviews +/− meta-analyses
 RCTsOutcomes
• Outcomes:
• Effectiveness of 
pharmacological 
and non-
pharmacologial 
interventions for 
the above
Study designs
• Systematic reviews 
+/- meta-analyses
• Randomzed 
controlled trials
• Quazi-RCTs
• Controlled clinical 
trials
• Controlled before-
after designs
• Interrupted time 
series studies
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 CCTs
 CBA designs
 ITS studies
 Case-series (for studies investigating the use of
epinephrine, and with a minimum of 10 patients)
We will appraise the evidence by looking at higher
levels of evidence such as systematic reviews and/or
meta-analyses of RCTs, together with individual RCTs.
However, we suspect that there will be limited informa-
tion available so we have opted to include quasi- RCTs
and CCTs (where non-random allocation of patients has
occurred), and EPOC study designs such as CBA study
designs (observations are made before and after the im-
plementation of an intervention) and ITS studies (where
observations at multiple time-points before and after
and intervention are made) [19]. Case-series, despite be-
ing lower forms of evidence, will be included as advice
from experts at the EAACI suggests that studies looking
at the use of epinephrine for managing acute anaphylaxis
will be missed by the other study designs.
Exclusion criteria
 Reviews, discussion papers, non-research letters and
editorials
 Qualitative studies
 Case studies
 Animal studies
Study selection
The titles will be checked independently by two reviewers
according to the above selection criteria and categorised
as: included, not included and unsure. For those papers in
the unsure category we will retrieve the abstract and re-
categorise as above. Any discrepancies will be resolved by
consensus and, if necessary, a third reviewer will be
consulted. Full text copies of potentially relevant studies
will be obtained and their eligibility for inclusion inde-
pendently assessed. Studies that do not fulfil all of the
inclusion criteria will be excluded.
Quality assessment strategy
Quality assessments will independently be carried out on
each study by two reviewers using the relevant version of
the Critical Appraisal Skills Programme (CASP) quality
assessment tool for systematic reviews [20]. We will assess
the risk of bias of studies eligible for the review using the
criteria suggested by EPOC [21]. RCTs, CCTs and CBAs
will be assessed for generation of allocation sequence, con-
cealment of allocation, baseline outcome measurements,
baseline characteristics, incomplete outcome data, blinding
of outcome assessor, protection against contamination,selective outcome reporting and other risks of bias. For
ITS designs, we also assessed the independence of the
intervention from other changes, the pre-specified shape
of the intervention and if the intervention was unlikely to
affect data collection. These will draw on the principles
incorporated into the Cochrane EPOC guidelines for
assessing intervention studies [22] and the Strengthening
the Reporting of Observational Studies in Epidemiology
for assessing observational studies [23]. Similarly, we will
use the quality assessment form produced by the National
Institute for Health and Clinical Excellence (NICE) to help
critically appraise case series [24]. Any discrepancies will
be resolved by discussion or, if agreement can not be
reached, by arbitration by a third reviewer.
Analysis, data synthesis and reporting
Data will be independently extracted onto a customised
data extraction sheet by two reviewers, and any discrep-
ancies will be resolved by discussion or, if agreement can
not be reached, by arbitration by a third reviewer.
A descriptive summary with data tables will be pro-
duced to summarise the literature. If clinically and statis-
tically appropriate, meta-analysis using either fixed-effect
or random-effects modelling will be undertaken using
methods suggested by Agresti and Coul [25]. A narrative
synthesis of the data will also be undertaken.
This review has been registered with the International
Prospective Register of Systematic Reviews (PROSPERO)
and has registration number CRD42013003703 allocated
to it. The Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) checklist will be used
to guide the reporting of the systematic review [26].
Discussion
The main strengths of this systematic review include the
formal development of a review protocol, the range of
databases searched and the formal critical appraisal of
eligible studies. The preparatory work in developing the
protocol involved extensive discussions with experts
and based on these deliberations we decided a priori to
consider lower forms of evidence in relation to epineph-
rine as expert opinion was in consensus that other more
rigorous studies would be unethical/unfeasible to under-
take. The main limitations are those inherent to system-
atic reviews, namely that it is not possible to guarantee
that all relevant evidence was uncovered. This particularly
needs to be borne in mind given the known limitations in
relation to the sub-optimal coding of non-randomized
study designs in biomedical databases. This risk was to an
extent ameliorated by the extensive contact with experts
with a view to identifying additional potentially relevant
literature. We had hoped to be able to quantitatively
synthesize data, but this was not possible because of the
paucity of primary studies and the lack of comparable
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undertake a narrative summary of the evidence. There is
at present little in the way of robust evidence to guide
decisions on the acute and/or long-term management of
anaphylaxis. Given the risk of death and the considerable
morbidity associated with anaphylaxis these evidence gaps
need to be filled wherever possible; this systematic review
makes an attempt to do so.
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